WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular...
Hence then, the article about vanda pharmaceuticals announces fda acceptance of biologics license application filing for imsidolimab for the treatment of generalized pustular psoriasis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis )
Also on site :
- FIFA’s plan to raise billions from investors is sparking a backlash—one insider says Europe is angry because it could change soccer’s balance of power
- Monroe County committees vote to accept $160,000 Operation Stonegarden border security grant despite opposition
- Doc Talk Podcast: Director Sara Dosa On Her Oscar Contender ‘Time And Water’, Elegy For Iceland’s Disappearing Ice